Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Joseph M. Miller Sells 61,859 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now directly owns 633,515 shares in the company, valued at approximately $5,068,120. This represents a 8.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Aurinia Pharmaceuticals Stock Performance

Aurinia Pharmaceuticals stock traded up $0.10 during midday trading on Tuesday, reaching $8.08. 3,640,172 shares of the company’s stock were exchanged, compared to its average volume of 1,449,999. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22. The stock’s 50-day simple moving average is $8.13 and its 200 day simple moving average is $7.85.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in AUPH. Segall Bryant & Hamill LLC raised its position in shares of Aurinia Pharmaceuticals by 1.6% in the third quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after buying an additional 9,031 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the third quarter valued at approximately $3,330,000. Intech Investment Management LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the third quarter valued at approximately $262,000. Charles Schwab Investment Management Inc. raised its position in shares of Aurinia Pharmaceuticals by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after buying an additional 89,940 shares in the last quarter. Finally, FMR LLC raised its position in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 3,919 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.